PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
5.62%
Some net income increase while RVPH is negative at -69.43%. John Neff would see a short-term edge over the struggling competitor.
3.20%
D&A growth of 3.20% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
22.07%
SBC growth of 22.07% while RVPH is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
81.65%
Well above RVPH's 135.36% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.82%
AP growth well above RVPH's 78.94%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
28.44%
Lower 'other working capital' growth vs. RVPH's 178.22%. David Dodd would see fewer unexpected short-term demands on cash.
-17.77%
Negative yoy while RVPH is 81.37%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
18.75%
Operating cash flow growth below 50% of RVPH's 56.98%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
-1425.00%
Negative yoy CapEx while RVPH is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1425.00%
We reduce yoy invests while RVPH stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
Negative yoy issuance while RVPH is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.